Show Summary Details
Page of

Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment 

Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment
Chapter:
Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment
Author(s):

Jakob Møller Hansen

, Alexandra Maria Rahmann

, Jes Olesen

, and Messoud Ashina

DOI:
10.1093/med/9780199552764.003.0016
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 January 2022

Chapter 16 investigates the headache eliciting effect of VIP and its effect on brain haemodynamics, and showcases two studies to test the following hypotheses: Infusion of VIP induces headache and arterial dilatation in healthy volunteers (study I), and infusion of VIP induces migraine and arterial dilatation in patients with migraine without aura (study II).

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.